期刊
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
卷 27, 期 10, 页码 1060-1066出版社
WILEY
DOI: 10.1002/pds.4267
关键词
cancer diagnosis; pharmacoepidemiology; Taiwan National Health Insurance database; validity
资金
- Chang Gung Memorial Hospital, Linkou [CMRPG3F0831, CORP3E0141, CORP3E0152]
- Ministry of Science and Technology, Taiwan [105-2320-B-182A-007]
Purpose We aimed to evaluate the validity of cancer diagnosis in the National Health Insurance (NHI) database, which has routinely collected the health information of almost the entire Taiwanese population since 1995, compared with the Taiwan National Cancer Registry (NCR). MethodsResultsThere were 26,542,445 active participants registered in the NHI database between 2001 and 2012. National Cancer Registry and NHI database records were compared for cancer diagnosis; date of cancer diagnosis; and 1, 2, and 5year survival. In addition, the 10 leading causes of cancer deaths in Taiwan were analyzed. There were 908,986 cancer diagnoses in NCR and NHI database and 782,775 (86.1%) in both, with 53,192 (5.9%) in the NHI database only and 73,019 (8.0%) in the NCR only. The positive predictive value of the NHI database cancer diagnoses was 94% for all cancers; the positive predictive value of the 10 specific cancers ranged from 95% (lung cancer) to 82% (cervical cancer). The date of diagnosis in the NHI database was generally delayed by a median of 15days (interquartile range 8-18) compared with the NCR. The 1, 2, and 5year survival rates were 71.21%, 60.85%, and 47.44% using the NHI database and were 71.18%, 60.17%, and 46.09% using NCR data. ConclusionsRecording of cancer diagnoses and survival estimates based on these diagnosis codes in the NHI database are generally consistent with the NCR. Studies using NHI database data must pay careful attention to eligibility and record linkage; use of both sources is recommended.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据